Cargando…

DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases

The purpose of the hypothesis testing is to determine that apparent diffusion coefficient (ADC) as an early biomarker can predict the metastatic lymph nodes’ (LNs) response to neoadjuvant chemotherapy in advanced gastric cancer (GC) in early stage. From March 2011 to June 2015, 106 patients with adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jinman, Zhao, Weiwei, Ma, Wanling, Ren, Fang, Qi, Shun, Zheng, Jianmin, Wang, Xifu, Lv, Tianchu, Su, Zhanliang, Yin, Hong, Ren, Jing, Huan, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998555/
https://www.ncbi.nlm.nih.gov/pubmed/27043694
http://dx.doi.org/10.1097/MD.0000000000003236
_version_ 1782449965823426560
author Zhong, Jinman
Zhao, Weiwei
Ma, Wanling
Ren, Fang
Qi, Shun
Zheng, Jianmin
Wang, Xifu
Lv, Tianchu
Su, Zhanliang
Yin, Hong
Ren, Jing
Huan, Yi
author_facet Zhong, Jinman
Zhao, Weiwei
Ma, Wanling
Ren, Fang
Qi, Shun
Zheng, Jianmin
Wang, Xifu
Lv, Tianchu
Su, Zhanliang
Yin, Hong
Ren, Jing
Huan, Yi
author_sort Zhong, Jinman
collection PubMed
description The purpose of the hypothesis testing is to determine that apparent diffusion coefficient (ADC) as an early biomarker can predict the metastatic lymph nodes’ (LNs) response to neoadjuvant chemotherapy in advanced gastric cancer (GC) in early stage. From March 2011 to June 2015, 106 patients with advanced GC were enrolled in the study. Patients underwent conventional magnetic resonance imaging and functional diffusion weighted imaging before and 3 days, 7 days, 30 days, and 60 days following the standard chemotherapy. After surgery, among 3034 detected LNs, the positive group was divided into complete response (CR) group, partial response (PR) group, and stable disease (SD) group in accordance to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Mean ADCs, short/long diameters of LNs before chemotherapy between the whole positive and the negative LNs were compared by t test. Changes of mean ADCs in 3 groups were analyzed by 1-way ANOVA. The mean ADC of the whole positive LNs was (1.145 ± 0.014) × 10(−3) mm(2)/s, which was significantly lower than that of the whole negative LNs ([1.491 ± 0.010] × 10(−3) mm(2)/s; P < 0.05). The means of both short/long diameters in the whole positive LNs were significantly longer than those in the whole negative LNs (P < 0.05). In CR, PR, and SD groups, the mean ADC of metastatic LNs on the 3rd day, 7th day, 13th day, and 16th day following the chemotherapy were all higher than that of LNs before chemotherapy, respectively (all P < 0.05). In addition, significant difference was found between mean ADCs in any 2 time points (all P < 0.05), except between mean ADCs in the 3rd day and in the 7th day of the chemotherapy. In conclusion, ADC can be used as an early biomarker to predict the metastatic LNs’ response to neoadjuvant chemotherapy in advanced GC in early stage.
format Online
Article
Text
id pubmed-4998555
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-49985552016-09-06 DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases Zhong, Jinman Zhao, Weiwei Ma, Wanling Ren, Fang Qi, Shun Zheng, Jianmin Wang, Xifu Lv, Tianchu Su, Zhanliang Yin, Hong Ren, Jing Huan, Yi Medicine (Baltimore) 5700 The purpose of the hypothesis testing is to determine that apparent diffusion coefficient (ADC) as an early biomarker can predict the metastatic lymph nodes’ (LNs) response to neoadjuvant chemotherapy in advanced gastric cancer (GC) in early stage. From March 2011 to June 2015, 106 patients with advanced GC were enrolled in the study. Patients underwent conventional magnetic resonance imaging and functional diffusion weighted imaging before and 3 days, 7 days, 30 days, and 60 days following the standard chemotherapy. After surgery, among 3034 detected LNs, the positive group was divided into complete response (CR) group, partial response (PR) group, and stable disease (SD) group in accordance to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Mean ADCs, short/long diameters of LNs before chemotherapy between the whole positive and the negative LNs were compared by t test. Changes of mean ADCs in 3 groups were analyzed by 1-way ANOVA. The mean ADC of the whole positive LNs was (1.145 ± 0.014) × 10(−3) mm(2)/s, which was significantly lower than that of the whole negative LNs ([1.491 ± 0.010] × 10(−3) mm(2)/s; P < 0.05). The means of both short/long diameters in the whole positive LNs were significantly longer than those in the whole negative LNs (P < 0.05). In CR, PR, and SD groups, the mean ADC of metastatic LNs on the 3rd day, 7th day, 13th day, and 16th day following the chemotherapy were all higher than that of LNs before chemotherapy, respectively (all P < 0.05). In addition, significant difference was found between mean ADCs in any 2 time points (all P < 0.05), except between mean ADCs in the 3rd day and in the 7th day of the chemotherapy. In conclusion, ADC can be used as an early biomarker to predict the metastatic LNs’ response to neoadjuvant chemotherapy in advanced GC in early stage. Wolters Kluwer Health 2016-04-01 /pmc/articles/PMC4998555/ /pubmed/27043694 http://dx.doi.org/10.1097/MD.0000000000003236 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5700
Zhong, Jinman
Zhao, Weiwei
Ma, Wanling
Ren, Fang
Qi, Shun
Zheng, Jianmin
Wang, Xifu
Lv, Tianchu
Su, Zhanliang
Yin, Hong
Ren, Jing
Huan, Yi
DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases
title DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases
title_full DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases
title_fullStr DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases
title_full_unstemmed DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases
title_short DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases
title_sort dwi as a quantitative biomarker in predicting chemotherapeutic efficacy at multitime points on gastric cancer lymph nodes metastases
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998555/
https://www.ncbi.nlm.nih.gov/pubmed/27043694
http://dx.doi.org/10.1097/MD.0000000000003236
work_keys_str_mv AT zhongjinman dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT zhaoweiwei dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT mawanling dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT renfang dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT qishun dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT zhengjianmin dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT wangxifu dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT lvtianchu dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT suzhanliang dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT yinhong dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT renjing dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases
AT huanyi dwiasaquantitativebiomarkerinpredictingchemotherapeuticefficacyatmultitimepointsongastriccancerlymphnodesmetastases